SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Results of Operations and Financial Condition

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On May3, 2017, Second Sight Medical Products, Inc. (the
Company) announced its financial and
operating results for the quarter ended March31, 2016. A copy of
the Companys press release entitled Second Sight Reports First
Quarter 2017 Financial Results is furnished as Exhibit99.1 to
this Current Report on Form8-K.

In accordance with General Instruction B.2 of Form8-K, the
information in this Item shall not be deemed filed for the
purpose of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), nor shall
it be deemed incorporated by reference in any filing.

ITEM7.01. REGULATION FD
DISCLOSURE

On May3, 2017, the Company issued the press release described
above in Item 2.02 of this Current Report on Form8-K. A copy of
the press release is attached hereto as Exhibit99.1.

The Company conducted a conference call to discuss these results
on May3, 2017, that was accessible live over the telephone by
dialing 1-(800) 786-6018 (or dialing1-(212) 231-2927from outside
the U.S.). As described in the press release, all statements in
the teleconference other than historical financial information,
may be deemed to be forward-looking statements within the meaning
of Section27A of the Securities Act of 1933, as amended, and
Section21E of the Exchange Act. Although the Company believes the
expectations expressed in such forward-looking statements are
based on reasonable assumptions, such statements are not
guarantees of future performance and actual results or
developments may differ materially from those in the
forward-looking statements. The Company disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise, except as required by law.

The conference call was broadcast live and was made available
shortly after completion of the call for replay for 30 days. The
replay can be accessed by dialing (800) 633-8284 (U.S.) or (402)
977-9140 (International). The conference ID for the replay is
21850167.

In accordance with General Instruction B.2 of Form8-K, the
information in this Item shall not be deemed filed for the
purpose of Section18 of the Exchange Act, nor shall it be deemed
incorporated by reference in any filing.

ITEM9.01. FINANCIAL STATEMENTS AND
EXHIBITS

About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Recent Trading Information

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) closed its last trading session down -0.02 at 1.27 with 511,915 shares trading hands.